The effect of medical therapy and islet cell transplantation on diabetic nephropathy: An interim report

被引:39
作者
Fung, Michelle A. [1 ]
Warnock, Garth L. [1 ]
Ao, Ziliang [1 ]
Keown, Paul [1 ]
Meloche, Mark [1 ]
Shapiro, R. Jean [1 ]
Ho, Stephen [1 ]
Worsley, Dan [1 ]
Meneilly, Graydon S. [1 ]
Al Ghofaili, Khalid [1 ]
Kozak, Sharon E. [1 ]
Tong, Suet On [1 ]
Trinh, Mary [1 ]
Blackburn, Lorraine [1 ]
Kozak, Robert M. [1 ]
Fensom, Blake A. [1 ]
Thompson, David M. [1 ]
机构
[1] Univ British Columbia, Dept Med, Vancouver, BC V5Z 1M9, Canada
关键词
islet transplantation; type; 1; diabetes; diabetic nephropathy;
D O I
10.1097/01.tp.0000265502.92321.ab
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. The effect of islet cell transplantation (ICT) on renal function in type 1 diabetes is uncertain and some recent studies report a significant decline in estimated glomerular filtration rate (GFR) and worsening of albuminuria. Methods. We are conducting a prospective crossover study comparing medical treatment with islet transplantation on the progression of diabetic complications, including renal function. The primary endpoint is change in GFR measured by Tc-99m-diethylenetriaminepentaacetate with secondary endpoints including estimated GFR and albumin excretion. Results. We have followed 21 patients after islet transplantation a median of 29 months (range 13-45) and compared their results with medically treated patients followed a median 29.5 months (range 13-56). There is no difference in the rate of decline in measured GFR between medically treated patients (-0.35 +/- 0.89; 95% CI: -0.57 to -0.13 mL/min/month/1.73 m(2)) and those after ICT (-0.31 +/- 1.18; 95% CI: -0.61 to -0.01) and neither is significantly different from that expected for the general population. The rate of decline in our estimated GFR results is lower than that reported in other studies and we did not find any worsening of albuminuria. Conclusions. We do not find evidence of worsening of renal function after islet transplantation compared with medically treated patients.
引用
收藏
页码:17 / 22
页数:6
相关论文
共 42 条
[1]  
[Anonymous], 2004, DIABETES CARE, DOI DOI 10.2337/DIACARE.27.5.1240-A
[2]   Improved renal function after conversion from tacrolimus/sirolimus to tacrolimus/mycophenolate mofetil in kidney transplant recipients [J].
Augustine, JJ ;
Chang, PC ;
Knauss, TC ;
Aeder, MI ;
Bodziak, KA ;
Schulak, JA ;
Hricik, DE .
TRANSPLANTATION, 2006, 81 (07) :1004-1009
[3]   Preserving renal function in adults with hypertension and diabetes: A consensus approach [J].
Bakris, GL ;
Williams, M ;
Dworkin, L ;
Elliott, WJ ;
Epstein, M ;
Toto, R ;
Tuttle, K ;
Douglas, J ;
Hsueh, W ;
Sowers, J .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2000, 36 (03) :646-661
[4]  
Blaufox MD, 1996, J NUCL MED, V37, P1883
[5]  
*CAN DIAB ASS, 2003, 2003 CLIN PRACT GUID
[6]   A Randomized long-term trial of tacrolimus/sirolimus versus tacrolimums/mycophenolate versus cyclosporine/sirolimus in renal transplantation: Three-year analysis [J].
Ciancio, G ;
Burke, GW ;
Gaynor, JJ ;
Ruiz, P ;
Roth, D ;
Kupin, W ;
Rosen, A ;
Miller, J .
TRANSPLANTATION, 2006, 81 (06) :845-852
[7]   PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE [J].
COCKCROFT, DW ;
GAULT, MH .
NEPHRON, 1976, 16 (01) :31-41
[8]   Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction [J].
Diekmann, F ;
Budde, K ;
Oppenheimer, F ;
Fritsche, L ;
Neumayer, HH ;
Campistol, JM .
AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 (11) :1869-1875
[9]   K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification - Foreword [J].
Eknoyan, G ;
Levin, NW .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2002, 39 (02) :S14-S266
[10]   Acute rapamycin nephrotoxicity in native kidneys of patients with chronic glomerulopathies [J].
Fervenza, FC ;
Fitzpatrick, PM ;
Mertz, J ;
Erickson, SB ;
Liggett, S ;
Popham, S ;
Wochos, DN ;
Synhavsky, A ;
Hippler, S ;
Larson, TS ;
Bagniewski, SM ;
Velosa, JA .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2004, 19 (05) :1288-1292